Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Zenas BioPharma (Nasdaq: ZBIO) granted an aggregate 51,075 restricted stock units (RSUs) on May 15, 2026 to newly hired employees as inducement awards under Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments from May 15, 2027 through May 15, 2030 under the 2026 Inducement Plan.
Positive
- 51,075 RSUs granted to support recruiting and retention of new employees
- Four-year vesting schedule may align new hires with long-term shareholder interests
Negative
- New RSU issuance can create modest equity dilution for existing shareholders
News Market Reaction – ZBIO
In the May 19 session, ZBIO gained 5.50%, reflecting a notable positive market reaction. Argus tracked a peak move of +7.9% during that session. Argus tracked a trough of -3.1% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Clinical trial update | Positive | +4.0% | First subject dosed in Phase 1 ZB021 trial with supportive preclinical data. |
| May 13 | Earnings and pipeline | Positive | +4.0% | Q1 2026 results, strong cash of $718.5M and multiple late-stage programs. |
| Apr 17 | Inducement grants | Neutral | -4.2% | 41,475 RSUs granted to new hires under 2026 Inducement Plan. |
| Mar 27 | Financing offering | Negative | -16.1% | Pricing of $300M concurrent convert and equity offerings for pipeline funding. |
| Mar 26 | Proposed offerings | Negative | -16.1% | Announcement of proposed convertible notes and equity offerings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Financing/offering headlines have coincided with sharp declines, while clinical and earnings updates have seen gains. Prior inducement grants drew a modest negative reaction.
Over recent months, ZBIO combined pipeline progress with significant financing. On Mar 26–27, 2026, proposed and priced offerings of notes and equity coincided with a -16.07% move. An inducement grant on Apr 17, 2026 saw a -4.22% reaction. In contrast, a May 13, 2026 clinical update and Q1 2026 earnings/portfolio summary each coincided with a +4.02% move. Today’s additional inducement awards fit the governance/hiring pattern rather than a new clinical or financing catalyst.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
inducement plan regulatory
restricted stock units (rsus) financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on May 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted an aggregate of 51,075 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
The RSUs will vest in four (4) equal installments over a four-year period, with vesting as to twenty-five percent (
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a preclinical, potentially best-in-class, oral, IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com
